These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 23763259)

  • 1. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
    Mortensen C; Karlsen S; Grønbæk H; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F
    Liver Int; 2013 Oct; 33(9):1309-15. PubMed ID: 23763259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation.
    Laursen TL; Rødgaard-Hansen S; Møller HJ; Mortensen C; Karlsen S; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F; Grønbaek H
    Liver Int; 2017 Apr; 37(4):569-575. PubMed ID: 27706896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of markers of bacterial translocation with immune activation in decompensated cirrhosis.
    Mortensen C; Jensen JS; Hobolth L; Dam-Larsen S; Madsen BS; Andersen O; Møller S; Bendtsen F
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1360-6. PubMed ID: 25357217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
    Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.
    Han G; Qi X; He C; Yin Z; Wang J; Xia J; Yang Z; Bai M; Meng X; Niu J; Wu K; Fan D
    J Hepatol; 2011 Jan; 54(1):78-88. PubMed ID: 20932597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histopathological investigation of the transjugular intrahepatic portocaval shunt (TIPS)].
    Ziarkiewicz-Wróblewska B; Wróblewski T; Górnicka B; Michałowicz B; Rowiński O; Bogdańska M; Krawczyk M
    Przegl Lek; 2001; 58(11):992-4. PubMed ID: 11987842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
    Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
    Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.
    Holland-Fischer P; Grønbæk H; Sandahl TD; Moestrup SK; Riggio O; Ridola L; Aagaard NK; Møller HJ; Vilstrup H
    Gut; 2011 Oct; 60(10):1389-93. PubMed ID: 21572121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites.
    Nair S; Singh R; Yoselewitz M
    J Vasc Interv Radiol; 2004 Dec; 15(12):1431-4. PubMed ID: 15590801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding.
    Rössle M; Haag K; Ochs A; Sellinger M; Nöldge G; Perarnau JM; Berger E; Blum U; Gabelmann A; Hauenstein K
    N Engl J Med; 1994 Jan; 330(3):165-71. PubMed ID: 8264738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy
    Jiang TT; Luo XP; Sun JM; Gao J
    World J Gastroenterol; 2017 Nov; 23(41):7470-7477. PubMed ID: 29151701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of immunity and bacterial translocation in cirrhosis.
    Mortensen C
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term hemodynamic effects of transjugular intrahepatic portosystemic shunts: a Doppler/manometric correlative study.
    Lafortune M; Martinet JP; Denys A; Patriquin H; Dauzat M; Dufresne MP; Colombato L; Pomier-Layrargues G
    AJR Am J Roentgenol; 1995 Apr; 164(4):997-1002. PubMed ID: 7726065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage.
    Sahagun G; Benner KG; Saxon R; Barton RE; Rabkin J; Keller FS; Rosch J
    Am J Gastroenterol; 1997 Sep; 92(9):1444-52. PubMed ID: 9317060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transjugular portosystemic shunt in chronic portal vein occlusion: importance of segmental portal hypertension in cavernous transformation of the portal vein.
    Walser EM; Soloway R; Raza SA; Gill A
    J Vasc Interv Radiol; 2006 Feb; 17(2 Pt 1):373-8. PubMed ID: 16517786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.